A set of uncommon, sometimes lethal lymphoproliferative illnesses is referred to as Castleman disease (CD). For a study, researchers examined data from deceased patients in the ACCELERATE registry and compared it to matched controls to identify characteristics related to CD mortality.
All deceased CD patients, matched controls, and a subset of patients with idiopathic multicentric Castleman disease (iMCD) were included in the analysis of demographic, therapeutic, and laboratory data. About 10 of the 140 patients in ACCELERATE with a CD diagnosis were deceased. Six of the 72 patients with confirmed iMCD had passed away. In comparison to the matched-control group, the dead CD cohort experienced more hospitalizations annually, higher overall hospitalization rates, more days spent in the hospital per month, and more treatment regimens annually.
When compared to controls, the dead cohort’s absolute lymphocyte count at months 3 and 6 was considerably lower, according to an analysis of laboratory results. There was a larger percentage of deceased iMCD patients with iMCD-TAFRO cases (thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal failure, and organomegaly). International normalized ratio, platelet count, and immunoglobulin M were all considerably lower in the deceased iMCD group.
The findings suggested that patients who have fatal and non-fatal outcomes may differ, and they also offer some first recommendations for factors that need more analysis.